• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Theravance

Theravance

  1. Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

    Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

  2. Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress

    Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress

  3. Innoviva to Participate in Morgan Stanley’s Global Healthcare Unplugged Conference on September 12

    Innoviva to Participate in Morgan Stanley’s Global Healthcare Unplugged Conference on September 12

  4. Innoviva to Participate in Baird Global Healthcare Conference on September 7

    Innoviva to Participate in Baird Global Healthcare Conference on September 7

1

©2017 Morningstar Advisor. All right reserved.